The lancet oncology
-
The lancet oncology · Aug 2010
Multicenter StudySafety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Results of two phase 3 trials have shown first-line bevacizumab in combination with chemotherapy improves clinical outcomes in patients with advanced or recurrent non-squamous non-small-cell lung cancer (NSCLC). The SAiL (MO19390) study was undertaken to assess the safety and efficacy of first-line bevacizumab combined with standard chemotherapy regimens in clinical practice. ⋯ F Hoffmann-La Roche Ltd.
-
The lancet oncology · Aug 2010
Randomized Controlled TrialMortality results from the Göteborg randomised population-based prostate-cancer screening trial.
Prostate cancer is one of the leading causes of death from malignant disease among men in the developed world. One strategy to decrease the risk of death from this disease is screening with prostate-specific antigen (PSA); however, the extent of benefit and harm with such screening is under continuous debate. ⋯ The Swedish Cancer Society, the Swedish Research Council, and the National Cancer Institute.